Charles Ryan on Practical Considerations in the Use of Novel Hormone Agents in the Post-ADT Setting
Practical Considerations in the Use of Novel Hormone Agents in the mCRPC Patient
Dr. Ryan delivers a concise presentation on clinical considerations in selecting treatment for the mCRPC patient. He walks though discussions on the Right Patient - the Right Therapy - Right Time - Right Patient. He also presents his objectives in determining treatment after ADT fails on its own. He looks to Preserve both Quality of Life and Performance Status, while treating with an agent that will Prevent pain, complications (e.g. SRE’s) and decline in performance status with an agent that will prolong life. Enjoy this state of the art approach presented by Charles Ryan, MD.
Charles J. Ryan, MD
Professor of Clinical Medicine
Division of Hematology / Oncology
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
Charles J. Ryan, MD is a Professor of Medicine in the Division of Hematology / Oncology at the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF) where he is the leader of the Genitourinary Medical Oncology Program. He received his MD from the University of Wisconsin in Madison and completed his residency in internal medicine at the University of Wisconsin Hospital and Clinics, where he also served as Chief Resident. He completed a fellowship in medical oncology in the Department of Medicine at Memorial Sloan-Kettering Cancer Center and the Joan and Sanford I. Weill Medical College of Cornell University in New York.
His clinical practice focuses predominantly on advanced prostate cancer as well as germ cell (testicular) tumors and other malignancies of the genitourinary tract.
His clinical and research work centers on the design and conduct of clinical trials of novel therapies for advanced prostate cancer, specifically secondary hormonal therapies targeting adrenal androgen signaling, insulin growth factor inhibitors, androgen receptor targeted therapy and chemotherapy. In addition to clinical trials, Dr. Ryan collaborates with many laboratories researching the role of the androgen receptor and other signaling mechanisms in prostate cancer patients.
Dr. Ryan is a member of several honor societies and is the recipient of a Leadership and Service Award and the John Kimberly Curtis Award from the University of Wisconsin Medical School. He received the American College of Physicians/ American Society of Internal Medicine Evergreen Award in 2000 and the American Society of Clinical Oncology Merit Award and Cancer And Leukemia Group B: Young Investigator Award, both in 2003. He was awarded the Donald Coffey Career Development Award from the Prostate Cancer Foundation in 2006 and a California Coalition to Cure Prostate Cancer Award in 2007.